During the recent annual American College of Cardiology meeting, researchers announced that adding a drug that stalls cholesterol absorption from the gut to treatment with a statin-lowering drug, which stops cholesterol production in the liver, is more beneficial than statin treatment alone in reducing low-density lipoprotein (LDL) cholesterol.
The EASE trial included 3030 patients on stable doses of statins who had not reached LDL target levels.Two thirds of the participants were randomized to take statins plus Zetia (ezetimibe) or statins only for 6 weeks. The results of the trial showed that combination therapy lowered LDL cholesterol by 6%, as opposed to a 3% reduction with single therapy, in a 6-week comparison of the 2 treatments. Lead author Thomas A. Pearson, MD, PhD, noted that combination therapy was effective across ages, genders, and races. In fact, 71% of the total group on combination therapy achieved target LDL cholesterol levels.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs